John Rountree, partner at Novasecta, discusses how the pharmaceutical industry is reacting to U.S. President Donald Trump's delayed health care bill. » Read More
After an experimental painkiller designed to be safer to use has outperformed in testing, Nektar Therapeutics is exploring next steps. » Read More
Allergan said it would buy Zeltiq Aesthetics for about $2.48 billion to gain access to its flagship body contouring technology.
Marathon said the muscular dystrophy drug will cost $89,000 a year, but that the company will provide a "robust" assistance program for uninsured patients.
Discussing the potential downside to pharmaceutical companies developing cures with Dr. Peter Bach, Memorial Sloan Kettering Center for Health Policy, and Brian Skorney, Baird biotechnology analyst. CNBC's Meg Tirrell also weighs in.
The pharma bro Shkreli previously won permission to speak at two other universities, but neither event happened because of protests.
David Gortler, associate professor at Georgetown University, says it is good that people are having conversations on the FDA but drug pricing remains complicated.
The "Fast Money" traders discuss the trade on Gilead, which is down about 9 percent.
A new SEC filing shows that Shkreli is involved in a tech start-up whose executives include a long-time Shkreli associate.
Sources said there is a significant gap over the company's valuation between Tesaro and potential acquirers.
Shares of Gilead Sciences are in the red after the drugmaker issued a weak sales forecast for its hepatitis C drugs.
Gilead said it predicts 2017 hepatitis C drug sales of $7.5 billion to $9 billion, lower than the $12 billion Wall Street had expected.
See which stocks are making moves after the bell on Tuesday.
CNBC's Meg Tirrell takes a closer look at drugs with the biggest exposure to Medicare spending, as President Trump leans towards Medicare negotiation. The "Fast Money" traders weigh in.
Lyme disease testing could be revolutionized thanks to new nanotrap technology that detects the disease in a whole new way.
Express Scripts said despite the double-digit increase, costs for employers rose just 2.5 percent across all prescription drugs.
Senator Klobuchar wants drugmaker Kaleo to explain the $4,500 price tags on its autoinjector devices for opioid overdose and food allergies.
CNBC's Meg Tirrell tries out Quest Diagnostics' Blueprint for Athletes blood test.
After years of ignoring the dangers of concussions, the NFL and scientific community are doing research to improve diagnosis and treatment.
The "Fast Money" traders digest Amazon's and Amgen's earnings reported after the bell on Thursday.
Rhenu Bhuller, partner at Frost & Sullivan, says that the deal would give Reckitt Benckiser access to markets in Asia.
More than $270 billion in worldwide mergers and acquisitions were announced in January, but foreign deals with the U.S. are lagging.
Get the best of CNBC in your inbox